Boehringer Ingelheim and Zealand Pharma A/S announced that the US Food and Drug Administration has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis . The Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need. BI 456906 is currently being evaluated in a Phase II study in adults with NASH and liver fibrosis (F2/F3) with and without diabetes.
- Read more about Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/boehringer-ingelheim-and-zealand-pharma-receive-fda-fast-track-designation-for-investigational-treatment-for-nash
No comments:
Post a Comment